NCT05676073View on ClinicalTrials.gov

Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

December 8, 2022

Primary Completion Date

December 30, 2022

Study Completion Date

January 27, 2023

Conditions
COVID-19
Interventions
DRUG

SHEN26 dose 1

Specification: 200mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).

DRUG

SHEN26 dose 2

Specification: 400mg/capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).

DRUG

SHEN26 placebo

Placebo matching the SHEN26 capsule. Subjects will receive 10 oral doses twice daily (after breakfast and dinner; Q12h±2h) from Day 1 to Day 5 (or Day 1 to Day 6).

Trial Locations (4)

510317

Guangdong Second Provincial General Hospital, Guangzhou

518112

The Third People's Hospital of Shenzhen, Shenzhen

Unknown

Shenzhen Longhua District People's Hospital, Shenzhen

Shijiazhuang Fifth Hospital, Shijiazhuang

All Listed Sponsors
lead

Shenzhen Kexing Pharmaceutical Co., Ltd.

NETWORK